You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德堅定兑現股東承諾 16個月完成4次共計40億元回購註銷

6月23日晚間,藥明康德(603259.SH/2359.HK)發佈公吿,年內第二次股份回購方案已於6月20日全部實施完畢。此次回購金額約10億元,回購的股份1577.54萬股已於6月24日悉數註銷。

緊接着,6月24日晚,藥明康德再發公吿稱,2025年第一次股份回購將按計劃繼續推進。上述兩份回購方案相互獨立,這意味着2025年尚未過半,藥明康德已進行了兩輪10億級別的回購.

藥明康德向來有通過大手筆分紅回購回報股東的傳統。僅在2024年,藥明康德就實施了3輪註銷式回購,合計金額達30億元。另據iFinD統計,自2018年上市以來,藥明康德累計歸母淨利潤達437.16億元,累計現金分紅達139.30億元,平均股息支付率為31.87%充分體現了藥明康德對股東價值的重視。

(圖片來源:iFinD)

自2024年4月新"國九條"正式出台,市值管理已逐漸成為A股上市公司工作的重點。新"國九條"特別強調"引導上市公司回購股份後依法註銷",鼓勵上市公司運用回購等方式,促進投資價值合理反映公司質量。

目前正值新"國九條"施行一週年之際,A股公司回購已步入常態化階段,根據Wind數據,2025年以來,以市值管理為目的的回購規模比2024年同期增長了179%。而藥明康德在過去16個月內,4次已回購股份均全部註銷,以實際行動提升股東回報。

除了淨利潤以及分紅回購規模持續增長外,藥明康德在股價表現上也給投資者帶來了可觀的回報。根據藥明康德官微資料,上市七年間,A股股價增值7倍,H股股價增值3倍,遠超同期市場寬基指數和醫藥行業指數。

(圖片來源:藥明康德官微)

面對複雜的地緣環境,藥明康德展現出積極的應對姿態。2025年,公司計劃投入70-80億元建設中國、美國、歐洲及新加坡基地,進一步鞏固全球領先的CRDMO服務能力。這種"內生增長+外延擴張"的戰略,使藥明康德在動盪市場中展現出罕見的確定性,也為持續股東回報提供了紮實的業績支撐。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account